Hence, in this scenario, DNA‐damaging agents that induce similar types of DNA breaks should exhibit synergy with HDAC6 inhibitors in ARID1A‐mutated tumours, including endometrial cancer. This evidence concerns the gene HDAC6 and endometrial cancer.